Insilico Medicine’s CEO Dr. Alex Zhavoronkov recognised among global top one per cent for pharmacology and toxicology (IMAGE)

InSilico Medicine

Insilico Medicine’s CEO Dr. Alex Zhavoronkov recognised among global top one per cent for pharmacology and toxicology

Caption

Following previous honors in 2022 and 2024, this recognition highlights Dr. Zhavoronkov’s exceptional and sustained research influence, which forms the scientific foundation of Insilico’s end-to-end generative AI platform, Pharma.AI, and the company’s diverse AI-driven drug discovery pipeline.

Credit

Insilico Medicine

Usage Restrictions

No

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.